Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.The Motley Fool • 01/25/25
Prediction: 3 Stocks That'll Be Worth More Than Berkshire Hathaway 5 Years From NowThe Motley Fool • 01/25/25
Thurgood Marshall College Fund receives $25 million grant from Lilly Endowment for HBCU capacity buildingGlobeNewsWire • 01/24/25
Lilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcementPRNewsWire • 01/23/25
Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble?The Motley Fool • 01/23/25
The Zacks Analyst Blog Eli Lilly, Exxon Mobil, Costco and Flanigan'sZacks Investment Research • 01/23/25
This Best-of-Class Pharma Stock Could Soar 72% This Year According to Wall Street Insider24/7 Wall Street • 01/22/25
Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?CNBC • 01/21/25
Novo, Lilly Weight-Loss Drugs Reduce Risk of Alzheimer's, Study Shows. What It Means for the Stocks.Barrons • 01/21/25
Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity?The Motley Fool • 01/18/25
FDA Okays LLY's Omvoh for Second Inflammatory Bowel Disease ConditionZacks Investment Research • 01/16/25
FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel diseasePRNewsWire • 01/15/25